Announcements Trials

Browse Landscape

Status

No longer available 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 13 Precursor Cell Lymphoblastic Leukemia-Lymphoma 7 Leukemia, Biphenotypic, Acute 7 Leukemia 7 Recurrence 1 Colorectal Neoplasms 1 Acute Myeloid Leukemia With KMT2A Rearrangement 1

Interventions

Cyclophosphamide 153 Dexamethasone 141 Rituximab 85 fludarabine 79 Lenalidomide 72 Cytarabine 70 Bortezomib 64 fludarabine phosphate 63 Gemcitabine 62 venetoclax 54 Etoposide 53 pomalidomide 52 pembrolizumab 52 Paclitaxel 48 Cisplatin 48 Carboplatin 48 Peripheral Blood Stem Cell Transplantation 47 Filgrastim 40 Radiotherapy 39 Busulfan 37 Calcium Dobesilate 36 Methotrexate 34 Melphalan 34 Bevacizumab 33 carfilzomib 32 Cyclosporine 32 Azacitidine 32 Mycophenolic Acid 30 Vincristine 29 Bendamustine Hydrochloride 29

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × revumenib × Clear all

NCT05918913 2025-09-05

Expanded Access Program for Revumenib

Syndax Pharmaceuticals

No longer available

Other hematologic neoplasm

Leukemia, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡